×
About 253,386 results

ALLMedicine™ Type 2 Diabetes Center

Research & Reviews  115,591 results

Type 2 diabetes and COPD: treatment in the right healthcare setting? An observational s...
https://doi.org/10.1186/s12875-021-01424-w 10.1186/1756-0500-7-497 10.1155/2016/6989453 10.1016/j.diabres.2020.108072 10.1186/1477-7525-1-13 10.1136/thx.54.7.581 10.1016/j.cnur.2017.04.007 10.1093/gerona/gls161 10.1370/afm.983 10.1016/j.gaceta.2013.03.002 10.1016/j.ccm.2013.10.002 10.1111/dme.12472 10.1016/j.rmed.2016.07.015
BMC Family Practice; Willink RP, Vos RC et. al.

Apr 21st, 2021 - Type 2 diabetes (T2DM) and COPD are chronic medical conditions, for which patients need lifelong healthcare. The aim of this study is to examine in which healthcare setting patients with T2DM and COPD receive their care, and if this is the correct...

The therapeutic potential of GLP-1 receptor biased agonism.
https://doi.org/10.1111/bph.15497
British Journal of Pharmacology; Jones B

Apr 21st, 2021 - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for type 2 diabetes as they stimulate insulin release and promote weight loss through appetite suppression. Their main side effect is nausea. All approved GLP-1RAs are f...

Glucagon Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors...
https://doi.org/10.1111/tri.13883
Transplant International : Official Journal of the Europe... Ertuglu LA, Porrini E et. al.

Apr 21st, 2021 - Post-transplant diabetes mellitus (PTDM) is a common complication of solid organ transplantation and a major cause of increased morbidity and mortality. Additionally, solid organ transplant patients may have pre-existent type 2 diabetes mellitus (...

AMBULATORY NON-INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE UNITED STATES, 2015...
https://doi.org/10.1111/dom.14408
Diabetes, Obesity & Metabolism; Heyward J, Christopher J et. al.

Apr 21st, 2021 - Tens of millions of individuals in the United States have Type 2 diabetes, and most require treatment with glucose-lowering medications to manage the disease. To examine trends in non-insulin drug treatment of Type 2 diabetes, including first-line...

see more →

Guidelines  405 results

Draft Recommendation Statement: Screening for Prediabetes and Type 2 Diabetes Mellitus
https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/prediabetes-and-type-2-diabetes-mellitus-screening
US Preventative Services Task Force (USPSTF)

Mar 15th, 2021 - According to the Centers for Disease Control and Prevention’s (CDC’s) 2020 National Diabetes Statistics Report, an estimated 13% of all U.S. adults (age ≥18 years) have diabetes, and 34.5% meet criteria for prediabetes.1 The prevalence of prediabe...

Most COVID-19 hospitalizations due to four conditions
https://www.nih.gov/news-events/nih-research-matters/most-covid-19-hospitalizations-due-four-conditions
NIH Research Matters; National Institutes of Health (NIH)

Mar 8th, 2021 - Studies show that certain common medical conditions put people at higher risk for severe illness from COVID-19. These include metabolic disorders like type 2 diabetes and obesity, as well as heart conditions like high blood pressure (hypertension)...

Drug activates brown fat, improves glucose metabolism in healthy women
https://www.nih.gov/news-events/nih-research-matters/drug-activates-brown-fat-improves-glucose-metabolism-healthy-women
National Institutes of Health (NIH)

Feb 3rd, 2021 - The majority of adults in the U.S. carry too much fat in their bodies and are now considered overweight or obese. The last several decades have also seen a spike in related diseases of metabolism, such as type 2 diabetes.

Brown fat associated with less heart and metabolic disease
https://www.nih.gov/news-events/nih-research-matters/brown-fat-associated-less-heart-metabolic-disease
National Institutes of Health (NIH)

Feb 1st, 2021 - Too much white fat, a characteristic of obesity, has been shown to increase the risk of type 2 diabetes, high blood pressure, and other diseases. A less common type of fat, called brown fat, uses blood sugar and fat molecules to create heat and he...

Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785422/
Obesity Medicine; Pang J, Liu M et. al.

Jan 5th, 2021 - COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a pandemic since WHO made the statement on March 11, 2020. The infection is causing a high mortality in old people, especially those with obesity, type 2 di...

see more →

Drugs  2,593 results see all →

Clinicaltrials.gov  125,107 results

Glimepiride - glimepiride tablet-Solco Healthcare U.S., LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86acdd9e-8637-43e4-8bf7-b3a123b871b8

Aug 12th, 2021 - Glimepiride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. Limitations of Use Glimepiride tablets USP should not be used for the trea...

Type 2 diabetes and COPD: treatment in the right healthcare setting? An observational s...
https://doi.org/10.1186/s12875-021-01424-w 10.1186/1756-0500-7-497 10.1155/2016/6989453 10.1016/j.diabres.2020.108072 10.1186/1477-7525-1-13 10.1136/thx.54.7.581 10.1016/j.cnur.2017.04.007 10.1093/gerona/gls161 10.1370/afm.983 10.1016/j.gaceta.2013.03.002 10.1016/j.ccm.2013.10.002 10.1111/dme.12472 10.1016/j.rmed.2016.07.015
BMC Family Practice; Willink RP, Vos RC et. al.

Apr 21st, 2021 - Type 2 diabetes (T2DM) and COPD are chronic medical conditions, for which patients need lifelong healthcare. The aim of this study is to examine in which healthcare setting patients with T2DM and COPD receive their care, and if this is the correct...

The therapeutic potential of GLP-1 receptor biased agonism.
https://doi.org/10.1111/bph.15497
British Journal of Pharmacology; Jones B

Apr 21st, 2021 - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for type 2 diabetes as they stimulate insulin release and promote weight loss through appetite suppression. Their main side effect is nausea. All approved GLP-1RAs are f...

Glucagon Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors...
https://doi.org/10.1111/tri.13883
Transplant International : Official Journal of the Europe... Ertuglu LA, Porrini E et. al.

Apr 21st, 2021 - Post-transplant diabetes mellitus (PTDM) is a common complication of solid organ transplantation and a major cause of increased morbidity and mortality. Additionally, solid organ transplant patients may have pre-existent type 2 diabetes mellitus (...

see more →

News  9,609 results

Heart Benefits Follow T2D Remission With Rapid Weight Loss
https://www.medscape.com/viewarticle/949649

Apr 20th, 2021 - Calorie-restricted diets followed by gradual food reintroduction may not only lead to remission of type 2 diabetes but also normalise cardiovascular disease risk and heart age, the results of a UK analysis suggest. Moreover, the approach is transf...

CVD Remains Leading Cause of Death in Type 2 Diabetes
https://www.medscape.com/viewarticle/948849

Apr 5th, 2021 - Cardiovascular disease was the leading cause of death among the over 16,000 patients with type 2 diabetes (T2DM) who were enrolled in the SAVOR-TIMI 53 trial. Two-thirds (66.3%) of all 798 deaths after a median 2.1 years of follow-up were caused b...

Post-COVID Wave Ahead of Death, Disability From Chronic Disease
https://www.medscape.com/viewarticle/948824

Apr 5th, 2021 - As a result of the COVID-19 pandemic, the United States will likely face a tsunami of death and disability from common chronic diseases that will affect society for decades, Robert Califf, MD, former commissioner of the US Food and Drug Administra...

Lp(a) Lowering With Alirocumab Tied to Small Increase in Risk of Type 2 Diabetes
https://www.medscape.com/viewarticle/948542

Apr 1st, 2021 - NEW YORK (Reuters Health) - Lowering elevated lipoprotein(a) levels with the PCSK9 inhibitor alirocumab may be associated with a slightly increased risk of developing type-2 diabetes, but the benefit appears to outweigh the potential risk, new res...

Glucose-lowering Drugs and Risk of COVID-19 Mortality in People with T2D
https://www.medscape.com/viewarticle/948605

Apr 1st, 2021 - Takeaway Type 2 diabetes (T2D) patients prescribed metformin, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and sulfonylureas were at a lower risk of COVID-19-related mortality than those not prescribed these drugs.

see more →

Patient Education  81 results see all →